Disease Course in Pentosan Polysulfate Sodium–Associated Maculopathy After Drug Cessation
15m
·
JAMA Ophthalmology Author Interviews
·
Interview with Nieraj Jain, MD, author of Disease Course in Patients With Pentosan Polysulfate Sodium–Associated Maculopathy After Drug Cessation
The episode Disease Course in Pentosan Polysulfate Sodium–Associated Maculopathy After Drug Cessation from the podcast JAMA Ophthalmology Author Interviews has a duration of
15:37. It was first published
More episodes from JAMA Ophthalmology Author Interviews
Automated Machine Learning for Predicting DR Progression From Ultra-Widefield Retinal Images
Interview with Paolo S. Silva, MD, and Jennifer K. Sun, MD, MPH, authors Automated Machine Learning for Predicting Diabetic Retinopathy Progression From Ultra-Widefield Retinal Images. Hosted by Neil M. Bressler, MD.
Related Content:
- Automated Machine Learning for Predicting Diabetic Retinopathy Progression From Ultra-Widefield Retinal Images
Social Determinants of Health and Perceived Barriers to Care in Diabetic Retinopathy Screening
Interview with Sophia Y. Wang, MD, MS, author of Social Determinants of Health and Perceived Barriers to Care in Diabetic Retinopathy Screening. Hosted by Neil Bressler, MD.
Related Content:
- Social Determinants of Health and Perceived Barriers to Care in Diabetic Retinopathy Screening
Risk of Stroke, Myocardial Infarction, and Death After Retinal Artery Occlusion
Interview with Prithvi Mruthyunjaya, MD, MHS, author of Risk of Stroke, Myocardial Infarction, and Death After Retinal Artery Occlusion. Hosted by Neil M. Bressler, MD.
Related Content:
- Risk of Stroke, Myocardial Infarction, and Death After Retinal Artery Occlusion
Assessing Strategies to Reduce Carbon Footprint of the AAO Annual Meeting
Interview with Scott M. McClintic, MD, author of Assessing Strategies to Reduce the Carbon Footprint of the Annual Meeting of the American Academy of Ophthalmology. Hosted by Neil Bressler, MD.
Related Content:
- Assessing Strategies to Reduce the Carbon Footprint of the Annual Meeting of the American Academy of Ophthalmology
Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control
Interview with Michael X. Repka, MD, MBA, author of Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. Hosted by Neil Bressler, MD.
Related Content:
- Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control